<DOC>
	<DOCNO>NCT02713139</DOCNO>
	<brief_summary>The purpose study determine efficacy safety association clotrimazole 200mg metronidazole 0,75 % ( Clopistatin 5DT® ) whether superior compare metronidazole 100mg/g ( gynecologic Flagyl® ) clotrimazole 20mg/g ( Gino-Canesten® 3 ) syndromic treatment vaginal discharge different etiology .</brief_summary>
	<brief_title>Efficacy Safety Association Clotrimazole Metronidazole Treatment Vaginal Discharge From Different Etiologies .</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Discharge</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Subjects already start sexual activity ; Subjects complaint vaginal discharge receive treatment 30 day enrollment visit ; Subjects premenopausal period must usage acceptable contraceptive method ( oral contraceptive , injectable contraceptive , IUD , hormonal implant , hormone transdermal adhesive , tubal ligation ) surgically sterile ( bilateral oophorectomy hysterectomy ) ; accept utilize barrier contraceptive provide sponsor period study ; Subjects capacity comprehend understand participation clinical trial , manifest informed consent form , even help another person ( Legal representative ) . Subjects chronic disease ( diabetes mellitus , neoplasia , renal failure , tuberculosis ) clinical and/or laboratory find ( anamnesis , physical exam and/or laboratory test ) interpret , investigator 's opinion , risk subject 's participation clinical trial ; Menopausal woman ; Known hypersensibility product ' component ; Pregnant lactate woman ; Subjects active genital ulcer and/or Genital herpes diagnosis ; Diagnosis suspicion Inflammatory pelvic disease ; Diagnosis Vulvar condyloma acuminata ; Subjects usage systemic corticosteroid period superior 2 ( two ) month usage chemotherapeutics ; Transplanted subject ; Subjects history active autoimmune disease immune suppression ; Subjects usage medication therapy describe protocol item `` Prohibited Treatments '' ; Subjects participate clinical trial last 12 month ( Conselho Nacional de Saúde Resolução 251 , de 7 de agosto de 1997 , item III , subitem J ) , unless subject direct benefit , investigator opinion ; Subject kinship bond employee Sponsor Research center ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>vaginal</keyword>
	<keyword>discharge</keyword>
	<keyword>woman</keyword>
</DOC>